文献速递认知障碍与痴呆帕金森病与运动障碍

β-淀粉样蛋白与tau生物标志物及路易体痴呆临床表型

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.
PubMed 文献 · Neurology · 2020-09-28

多中心纳入417例很可能路易体痴呆(DLB)患者,按脑脊液或PET的β-淀粉样蛋白(A)和tau(T)阳性分为4组。A-T-最常见(39%),A+和T+随年龄增加,A+是认知表现较低的主要预测因素,T+与帕金森综合征和很可能快速眼动睡眠行为障碍频率较低相关。

要点

  • DLB中阿尔茨海默病病理常见,A-T-占39%,A+T-占32%,A+T+占15%,A-T+占13%。
  • A+随年龄增加,APOE ε4携带者增加更明显;A+是认知表现较低的主要预测因素。
  • T+与帕金森综合征和很可能快速眼动睡眠行为障碍频率较低相关,A+与T+无显著交互。

核心结论

  • DLB中阿尔茨海默病病理改变常见并与临床表型相关:β-淀粉样蛋白与认知损害相关,tau病理与DLB临床特征频率较低相关。

研究设计与样本

  • 多中心队列纳入417例很可能DLB患者(年龄45-93岁,女性31%)。
  • 欧洲队列用脑脊液β-淀粉样蛋白1-42和磷酸化tau判定A+和T+,Mayo Clinic队列用Pittsburgh compound B和AV-1451 PET判定。
  • 患者按A/T状态分为A-T-、A+T-、A-T+和A+T+四组。

主要发现

  • A-T-为最大组(39%),其次A+T-(32%)、A+T+(15%)、A-T+(13%)。
  • A-T-百分比随年龄下降,A+和T+在女性和男性中均随年龄增加。
  • A+在APOE ε4携带者中随年龄增加比非携带者更明显。
  • A+与T+共同考虑时,A+是认知表现较低的主要预测因素。
  • T+与帕金森综合征和很可能快速眼动睡眠行为障碍频率较低相关,A+与T+对临床表型无显著交互。

关键数值与推荐

  • A+由脑脊液β-淀粉样蛋白1-42或Pittsburgh compound B PET判定,T+由脑脊液磷酸化tau或AV-1451 PET判定。
  • 证据等级:Class II,支持很可能DLB中β-淀粉样蛋白与认知表现较低相关、tau病理与DLB临床特征频率较低相关。

临床怎么用

  • 在很可能DLB中可考虑检测β-淀粉样蛋白和tau生物标志物以辅助诊断、预后判断和疾病监测。
  • β-淀粉样蛋白阳性提示认知表现可能较低,tau阳性提示帕金森综合征和快速眼动睡眠行为障碍频率可能较低。
  • 这些发现对针对DLB疾病特异性蛋白的临床试验有参考意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+) and tau (T+) biomarkers was determined by CSF β-amyloid1-42 and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE ε4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. CONCLUSIONS: Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. β-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with probable DLB, β-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ferreira D, Przybelski SA, Lesnick TG, et al. β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology. 2020. PMID: 32989106. doi:10.1212/WNL.0000000000010943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。